Glossary
What is Clinical trial application (CTA)?
By Benedict Mehlmann, technology and product at Kodo Leads · Last updated
A clinical trial application (CTA) is the request to authorise a clinical trial with a medicinal product. In the EU, all new trials have been submitted through the CTIS portal since 31 January 2023 and are assessed jointly by the member states concerned under Regulation (EU) No 536/2014.
What the application contains
A CTA has two parts. Part I covers what is the same for all countries concerned: the protocol, the investigator's brochure and the IMPD (investigational medicinal product dossier) on quality, manufacturing and preclinical data of the investigational product. Part I is assessed jointly, led by a reporting member state. Part II covers what each country checks itself: informed consent, suitability of sites and investigators, insurance, data protection.
Deadlines under Regulation 536/2014
- Validation: 10 days to check completeness.
- Assessment of part I: 45 days from validation to the assessment report.
- Decision: 5 days, per member state.
Without requests for information that is about two months. Questions from the authorities extend the deadlines.
The pre-CTA phase
Before the first application, a biotech finishes preclinical work and prepares everything: GLP toxicology, scientific advice, IMPD and protocol, the first GMP batch with QP release under Annex 13, and the choice of CRO and sites. In this phase almost every service provider is hired for the first time.
How to spot a biotech in the pre-CTA phase
Companies usually say it themselves: an announced trial start on the pipeline page, “first-in-human” in a funding announcement, the first regulatory affairs hire, scientific advice or PRIME status at the EMA. Alone these are hints; together and dated they document the window.
How Kodo Leads helps with Clinical trial application (CTA)
Kodo finds the biotechs preparing their first CTA right now and proves it with the source: pipeline page, trial registry, regulatory decision, funding announcement or job ad. For regulatory consultancies, CROs, CDMOs and QP providers, this is when partners for the next years are chosen. More on the <a href="/en/solutions/pre-cta">Pre-CTA Report</a> page.
Frequently asked questions about Clinical trial application (CTA)
What is CTIS?
The EMA's Clinical Trials Information System, the single portal for clinical trial applications in the EU. All new applications have been filed there since 31 January 2023.
What is an IMPD?
The investigational medicinal product dossier: quality, manufacturing and control of the investigational product plus preclinical and, where available, clinical data. It is part of part I of the application.
How long does CTA approval take?
Under Regulation (EU) No 536/2014 about two months without questions: 10 days validation, 45 days assessment, 5 days decision. Requests for information extend this.
Related terms
SIC Codes and WZ Codes in B2B Sales Explained | Glossary Technographic Data (Technographics) | B2B Definition Sales Automation | B2B Guide for SMEs How Do I Find B2B Leads in Germany? | The Ultimate Guide What is Account Based Marketing (ABM)? | B2B Definition B2B Cold Calling | Strategies for Industry & Manufacturing B2B Web Scraping | Automated Lead Generation Guide All resources
Last updated on
Test us on your target customers. The first 10 companies are free.
Tell us your target companies. Within 24 hours you have 10 companies, each with occasion, contact and source. No subscription, no credit card.
Prefer to talk first? Talk to Joshua